Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma
Purpose: Introduction of lenalidomide has expanded the therapeutic options for refractory and recurrent multiple myeloma (MM) patients. However, the application of the approved doses may be difficult in some patients due to adverse effects. Experimental design: Therefore, we evaluated the efficacy a...
Main Authors: | Schmidt-Wolf, Ingo G. H., Glasmacher, Axel, Gorschlüter, Marcus, Schwamborn, Katharina, German Refractory Myeloma Study Group |
---|---|
Format: | Article |
Language: | deu |
Published: |
German Medical Science GMS Publishing House
2011-01-01
|
Series: | GMS German Medical Science |
Subjects: | |
Online Access: | http://www.egms.de/en/journals/gms/2011-9/000149.shtml |
Similar Items
-
A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan
by: Shang-Yi Huang, et al.
Published: (2017-09-01) -
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
by: Jiri Minarik, et al.
Published: (2021-01-01) -
LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
by: Patrizia Tosi
Published: (2013-06-01) -
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
by: Cirino Botta, et al.
Published: (2021-04-01) -
Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)